ClinicalTrials.gg

Program

Valproic Acid

Also written as “Divalproex Sodium”, “divalproex sodium” and “Sodium valproate”.

Its studies are mostly in Bipolar Disorder · Epilepsy · Migraine Disorders · Seizures · Schizophrenia, led by 11 companies.

Furthest: phase 4, since May 15, 200338 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott100 open or runningphase 3since May 15, 2003May 15, 2003none ahead
Dr. Reddy's Laboratories70 open or runningphase 1since Jan 25, 2010Jan 25, 2010none ahead
Sanofi40 open or runningphase 4since Dec 9, 2005Dec 9, 2005none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
AstraZeneca30 open or runningphase 4since Aug 29, 2005Apr 9, 2004none ahead
Novartis30 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Desitin Arzneimittel20 open or runningphase 1since Dec 21, 2023Dec 21, 2023none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
cerebral-therapeutics-llc10 open or runningphase 2since Sep 3, 2016Sep 3, 2016none ahead
hearthstone-alzheimer-care10 open or runningphase 1since Sep 12, 2005Sep 12, 2005none ahead
tecnoquimicas10 open or runningphase 4since Apr 11, 2019Apr 11, 2019none ahead

Also a collaborator on its studies: biopharma-services-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since May 15, 2003.

  1. Mar 25, 2008Phase 2 study in Pediatric EpilepsyAbbott · NCT00646711 · 16 enrolled · United States
  2. Mar 30, 2008Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00648076, NCT00647712
  3. Jan 30, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00834990, NCT00834639
  4. Mar 17, 2009Novartis's first study: phase 1 study in SeizuresNew to NovartisNovartis · NCT00864006 · 28 enrolled
  5. Jun 2, 20092 phase 1 studies in EpilepsyNovartis · NCT00913874, NCT00913848
  6. Sep 9, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00974441, NCT00974012
  7. Jan 25, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01056627, NCT01055938
  8. May 26, 20103 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01132196, NCT01132183, NCT01132170
  9. Apr 4, 20122 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01581788, NCT01581775
  10. Sep 3, 2016cerebral-therapeutics-llc's first study: phase 2 study in EpilepsyNew to cerebral-therapeutics-llccerebral-therapeutics-llc · NCT02899611 · 6 enrolled · Australia
  11. Sep 14, 2018Phase 1 study in EpilepsySanofi · NCT03681158 · 5 enrolled · United Kingdom
  12. Apr 11, 2019tecnoquimicas's first study: phase 4 study in HealthyNew to tecnoquimicastecnoquimicas · NCT03914534 · 30 enrolled · Colombia
  13. Dec 21, 2023Desitin Arzneimittel's first study: phase 1 study in Food-drug InteractionNew to Desitin ArzneimittelDesitin Arzneimittel · NCT06211283 · 28 enrolled · Canada
  14. Jan 10, 2024Phase 1 study in Multiple Drug UseDesitin Arzneimittel · NCT06214130 · 22 enrolled · Canada

TargetBeta

ALDH5A1 →read by rule
“Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06214130Multiple Drug Use · Canada1CompletedDesitin ArzneimittelNov 6, 202322
NCT06211283Food-drug Interaction · Canada1CompletedDesitin ArzneimittelOct 20, 202328
NCT03914534Healthy · Colombia4CompletedtecnoquimicasJul 31, 201830
NCT03681158Epilepsy · United Kingdom1CompletedSanofiApr 11, 20195
NCT02899611Epilepsy · Australia2Completedcerebral-therapeutics-llcJun 1, 20216
NCT01581788Healthy · India1CompletedDr. Reddy's LaboratoriesFeb 201154
NCT01581775Healthy · India1CompletedDr. Reddy's LaboratoriesJan 201154
NCT01132196Healthy · India1CompletedDr. Reddy's LaboratoriesSep 200634
NCT01132183Healthy · India1CompletedDr. Reddy's LaboratoriesMar 200734
NCT01132170Healthy · India1CompletedDr. Reddy's LaboratoriesSep 200634
NCT01056627Healthy · India1CompletedDr. Reddy's LaboratoriesJan 200734
NCT01055938Healthy · India1CompletedDr. Reddy's LaboratoriesJan 200734
NCT00974441Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200648
NCT00974012Healthy · United States1CompletedTeva Pharmaceutical IndustriesOct 200624
NCT00913874Epilepsy1CompletedNovartisOct 200530
NCT00913848Epilepsy1CompletedNovartisOct 200530
NCT00864006Seizures1CompletedNovartisOct 200628
NCT00834990Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200324
NCT00834639Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200324
NCT00648076Healthy · United States1CompletedViatrisDec 200440
NCT00647712Healthy · United States1CompletedViatrisDec 200438
NCT00646711Pediatric Epilepsy · United States2CompletedAbbottDec 200316
NCT00431522Bipolar Disorder · Turkey4CompletedSanofiOct 200658
NCT00271258Bipolar Disorder · France3CompletedSanofi200
NCT00264173Bipolar Disorder4CompletedSanofi270
NCT00195806Migraine Disorders · United States3CompletedAbbott315
NCT00195780Bipolar I Disorder · United States3CompletedAbbott227
NCT00195767Mania · United States3CompletedAbbott150
NCT00195754Migraine Disorders · United States3CompletedAbbott114
NCT00195741Migraine Disorders · United States3CompletedAbbott300
NCT00197834Dementia · United States1UNKNOWNhearthstone-alzheimer-care20
NCT00139074Bipolar Disorder · Denmark4TerminatedAstraZenecaJun 200617
NCT00114686Alcoholism · United States3CompletedAstraZeneca350
NCT00102713Seizures · United States3CompletedAbbott50
NCT00081380Bipolar Disorder · United States, Canada3CompletedAstraZeneca710
NCT00067431Epilepsies, Partial · United States3TerminatedAbbott300
NCT00067262Bipolar Disorder · United States3CompletedAbbott150
NCT00060905Bipolar Disorder · United States3CompletedAbbott370

How it is read

Names in the registry

  • “Divalproex Sodium”, 10 entries
  • “divalproex sodium”, 7 entries
  • “Sodium valproate”, 3 entries
  • “Valproic Acid”, 2 entries
  • “Valproic Acid 500 MG”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.